xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

383

ICAR SINONASAL TUMORS

117. Hermsen MA, Riobello C, García-Marín R, et al. Transla tional genomics of sinonasal cancers. Semin Cancer Biol . 2020;61:101-109. https://doi.org/10.1016/j.semcancer.2019.09. 016 118. Li J, Kan H, Zhao L, Sun Z, Bai C. Immune check point inhibitors in advanced or metastatic mucosal melanoma: a systematic review. Ther Adv Med Oncol . 2020;12:1758835920922028. https://doi.org/10.1177/ 1758835920922028 119. Unsal AA, Chung SY, Unsal AB, Baredes S, Eloy JA. A population-based analysis of survival for sinonasal rhab domyosarcoma. Otolaryngol Head Neck Surg . 2017;157(1):142 149. https://doi.org/10.1177/0194599817696292 120. Rushton L, Hutchings SJ, Fortunato L, et al. Occupational cancer burden in Great Britain. Br J Cancer . 2012;107(Suppl 1):S3-S7. https://doi.org/10.1038/bjc.2012.112 121. Pippard EC, Acheson ED. The mortality of boot and shoe mak ers, with special reference to cancer. Scand J Work Environ Health . 1985;11(4):249-255. https://doi.org/10.5271/sjweh.2223 122. Colombino M, Paliogiannis P. BRAF mutations and dysreg ulation of the MAP kinase pathway associated to sinonasal mucosal melanomas. J ClinMed . 2019;8(10):1577. https://doi. org/10.3390/jcm8101577 123. Turri-Zanoni M, Medicina D, Lombardi D, et al. Sinonasal mucosal melanoma: molecular profile and therapeutic impli cations from a series of 32 cases. HeadNeck . 2013;35(8):1066 1077. https://doi.org/10.1002/hed.23079 124. Zebary A, Jangard M, Omholt K, Ragnarsson-Olding B, Hansson J. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Br J Cancer . 2013;109(3):559-564. https://doi.org/10.1038/bjc.2013.373 125. Roxbury CR, Ishii M, Richmon JD, Blitz AM, Reh DD, Gallia GL. Endonasal endoscopic surgery in the manage ment of sinonasal and anterior skull base malignancies. Head Neck Pathol . 2016;10(1):13-22. https://doi.org/10.1007/s12105 016-0687-8 126. Chatelet F, Simon F, Bedarida V, et al. Surgical manage ment of sinonasal cancers: a comprehensive review. Cancers . 2021;13(16):3995. https://doi.org/10.3390/cancers13163995 127. Sato Y, Morita M, Takahashi HO, Watanabe N, Kirikae I. Combined surgery, radiotherapy, and regional chemotherapy in carcinoma of the paranasal sinuses. Cancer . 1970;25(3):571 579. https://doi.org/10.1002/1097-0142(197003)25:3 ⟨ 571::aid cncr2820250312 ⟩ 3.0.co;2-n 128. Knegt PP, Ah-See KW, vd Velden LA, Kerrebijn J. Adenocarci noma of the ethmoidal sinus complex: surgical debulking and topical fluorouracil may be the optimal treatment. ArchOto laryngol Head Neck Surg . 2001;127(2):141-146. https://doi.org/ 10.1001/archotol.127.2.141 129. Samant S, Robbins KT, Vang M, Wan J, Robertson J. Intra arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. Arch Oto laryngol Head Neck Surg . 2004;130(8):948-955. https://doi.org/ 10.1001/archotol.130.8.948 130. de Almeida JR, Su SY, Koutourousiou M, et al. Endonasal endoscopic surgery for squamous cell carcinoma of the sinonasal cavities and skull base: oncologic outcomes based on treatment strategy and tumor etiology: endonasal endo scopic surgery for SCC of the sinonasal cavities and skull base.

noma. OralOncol . 2013;49(5):413-419. https://doi.org/10.1016/ j.oraloncology.2012.12.011 103. Takahashi Y, Bell D, Agarwal G, et al. Comprehensive assess ment of prognostic markers for sinonasal squamous cell carcinoma. Head Neck . 2014;36(8):1094-1102. https://doi.org/ 10.1002/hed.23423 104. García-Inclán C, López F, Pérez-Escuredo J, et al. EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal ade nocarcinomas. CellOncol . 2012;35(6):443-450. https://doi.org/ 10.1007/s13402-012-0103-7 105. Franchi A, Fondi C, Paglierani M, Pepi M, Gallo O, Santucci M. Epidermal growth factor receptor expression and gene copy number in sinonasal intestinal type adenocarci noma. OralOncol . 2009;45(9):835-838. https://doi.org/10.1016/ j.oraloncology.2008.12.005 106. Volpi L, Bignami M, Lepera D, et al. Endoscopic endonasal resection of adenoid cystic carcinoma of the sinonasal tract and skull base. Laryngoscope . 2019;129(5):1071-1077. https:// doi.org/10.1002/lary.27485 107. Bell D, Bell AH, Bondaruk J, Hanna EY, Weber RS. In-depth characterization of the salivary adenoid cystic carcinoma tran scriptome with emphasis on dominant cell type. Cancer . 2016;122(10):1513-1522. https://doi.org/10.1002/cncr.29959 108. Ferrarotto R, Mitani Y, Diao L, et al. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J Clin Oncol . 2017;35(3):352-360. https://doi.org/10. 1200/jco.2016.67.5264 109. Ho AS, Kannan K, Roy DM, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet . 2013;45(7):791-798. https://doi.org/10.1038/ng.2643 110. Lopez DC, Wadley AE, London NR Jr. Emerging con cepts in sinonasal tumor research. Curr Opin Otolaryngol Head Neck Surg . 2022;30(1):33-39. https://doi.org/10.1097/ moo.0000000000000776 111. Lechner M, Liu J, Lund VJ. Novel biomarkers in sinonasal cancers: from bench to bedside. Curr Oncol Rep . 2020;22(10):106. https://doi.org/10.1007/s11912-020-00947-2 112. Classe M, Yao H, Mouawad R, et al. Integrated multi-omic analysis of esthesioneuroblastomas identifies two subgroups linked to cell ontogeny. Cell Rep . 2018;25(3):811.e5-821.e5. https://doi.org/10.1016/j.celrep.2018.09.047 113. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol . 2008;116(6):597-602. https:// doi.org/10.1007/s00401-008-0455-2 114. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol . 2010;28(14):2348 2355. 115. Mullard A. FDA approves first-in-class cancer metabolism drug. Nat Rev Drug Discov . 2017;16(9):593. https://doi.org/10. 1038/nrd.2017.174 116. Colombino M, Lissia A, Franco R, et al. Unexpected dis tribution of cKIT and BRAF mutations among southern Italian patients with sinonasal melanoma. Dermatology . 2013;226(3):279-284. https://doi.org/10.1159/000350683